Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1HER-2 Gene Amplification 1Esophageal Neoplasms 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 104Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × MM-111 × Clear all
NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Merrimack Pharmaceuticals

Phase 2 Terminated
84 enrolled 10 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡